X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (109) 109
oncology (92) 92
chemotherapy (66) 66
female (54) 54
male (51) 51
combined modality therapy (46) 46
adult (43) 43
radiotherapy (43) 43
antineoplastic combined chemotherapy protocols - therapeutic use (42) 42
hyperfractionated radiotherapy (40) 40
middle aged (40) 40
cancer (39) 39
index medicus (38) 38
child (34) 34
hyperfractionated radiation-therapy (32) 32
adolescent (31) 31
treatment outcome (31) 31
aged (30) 30
care and treatment (26) 26
survival rate (26) 26
hyperfractionated cyclophosphamide (25) 25
children (24) 24
child, preschool (23) 23
cyclophosphamide - administration & dosage (21) 21
hematology (21) 21
radiotherapy dosage (21) 21
survival analysis (21) 21
lung neoplasms - drug therapy (20) 20
neoplasm staging (20) 20
lung neoplasms - radiotherapy (19) 19
prognosis (19) 19
radiation-therapy (18) 18
retrospective studies (18) 18
antineoplastic agents - therapeutic use (17) 17
randomized trial (17) 17
survival (17) 17
vincristine - administration & dosage (17) 17
aged, 80 and over (16) 16
antineoplastic combined chemotherapy protocols - adverse effects (16) 16
disease-free survival (16) 16
pediatrics (16) 16
radiology, nuclear medicine & medical imaging (16) 16
carcinoma (15) 15
cisplatin (15) 15
concurrent chemotherapy (15) 15
doxorubicin (15) 15
hyper-cvad (15) 15
antineoplastic combined chemotherapy protocols - administration & dosage (14) 14
medicine & public health (14) 14
surgery (14) 14
vincristine (14) 14
childhood (13) 13
cyclophosphamide (13) 13
drug administration schedule (13) 13
lung neoplasms - pathology (13) 13
acute lymphocytic leukemia (12) 12
dose fractionation (12) 12
etoposide - administration & dosage (12) 12
glioma - drug therapy (12) 12
gliomas (12) 12
respiratory system (12) 12
tumors (12) 12
abridged index medicus (11) 11
carcinoma, non-small-cell lung - drug therapy (11) 11
clinical trials as topic (11) 11
glioma - radiotherapy (11) 11
pediatric-oncology-group (11) 11
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (11) 11
prognostic-factors (11) 11
acute lymphoblastic leukemia (10) 10
acute lymphocytic-leukemia (10) 10
adjuvant chemotherapy (10) 10
carboplatin (10) 10
carcinoma, non-small-cell lung - radiotherapy (10) 10
chemotherapy, adjuvant (10) 10
cisplatin - administration & dosage (10) 10
doxorubicin - administration & dosage (10) 10
glioma - therapy (10) 10
irradiation (10) 10
medulloblastoma (10) 10
oncology-group (10) 10
phase-ii trial (10) 10
remission induction (10) 10
research (10) 10
trial (10) 10
brain neoplasms - drug therapy (9) 9
carcinoma, non-small-cell lung - pathology (9) 9
clinical trials (9) 9
dexamethasone (9) 9
hematology, oncology and palliative medicine (9) 9
lung neoplasms - mortality (9) 9
lung neoplasms - therapy (9) 9
philadelphia chromosome (9) 9
precursor cell lymphoblastic leukemia-lymphoma - mortality (9) 9
radiotherapy, adjuvant (9) 9
therapy (9) 9
toxicity (9) 9
acute lymphoblastic-leukemia (8) 8
brain stem neoplasms - radiotherapy (8) 8
brain tumors (8) 8
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer, ISSN 0008-543X, 12/2004, Volume 101, Issue 12, pp. 2788 - 2801
BACKGROUND Modern intensive chemotherapy regimens have improved the prognosis for patients with adult acute lymphocytic leukemia (ALL). With these regimens,... 
acute lymphocytic leukemia (ALL) | hyperfractionated cyclophosphamide | vincristine | doxorubicin | long‐term follow‐up | and dexamethasone (Hyper‐CVAD) regimen | Acute lymphocytic leukemia (ALL) | Hyperfractionated cyclophosphamide | Long-term follow-up | And dexamethasone (Hyper-CVAD) regimen | Doxorubicin | Vincristine | MAINTENANCE CHEMOTHERAPY | COMPLETE REMISSION | STANDARD-RISK | BONE-MARROW-TRANSPLANTATION | ALLOGENEIC TRANSPLANT | CHILDHOOD | doxorubicin, and dexamethasone (Hyper-CVAD) regimen | THERAPY | ONCOLOGY | longterm follow-up | ACUTE LYMPHOBLASTIC-LEUKEMIA | CHILDRENS CANCER GROUP | GROUP-B | Doxorubicin - therapeutic use | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality | Risk | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Vincristine - administration & dosage | Adult | Bone Marrow - drug effects | Doxorubicin - administration & dosage | Dexamethasone - administration & dosage | Drug Administration Schedule | Remission Induction | Dexamethasone - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Survival Analysis | Vincristine - therapeutic use | Vincristine - adverse effects | Aged | Central Nervous System Neoplasms - drug therapy | Doxorubicin - adverse effects | Cyclophosphamide | Care and treatment | Dexamethasone | Dosage and administration | Acute lymphocytic leukemia | Drug therapy
Journal Article
Cancer, ISSN 0008-543X, 03/2004, Volume 100, Issue 6, pp. 1179 - 1185
BACKGROUND Hyperglycemia, which is not uncommon during the treatment of acute lymphocytic leukemia (ALL), has been shown to be an independent predictor of... 
hyperglycemia | vincristine | complications | and dexamethasone (hyper‐CVAD chemotherapy) | mortality | acute lymphocytic leukemia (ALL) | steroids | hyperfractionated cyclophosphamide | doxorubicin | complete remission duration (CRD) | Acute lymphocytic leukemia (ALL) | Hyperglycemia | Complete remission duration (CRD) | Complications | Mortality | Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD chemotherapy) | Steroids | INSULIN | ONCOLOGY | doxorubicin, and dexamethasone (hyper-CVAD chemotherapy) | hyperfractionated cyclophosphamide, vincristine | CANCER | Doxorubicin - therapeutic use | Cytarabine - therapeutic use | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Male | Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality | Antineoplastic Agents - therapeutic use | Cytarabine - adverse effects | Methotrexate - therapeutic use | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Infection - etiology | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Time Factors | Antineoplastic Agents - adverse effects | Adult | Female | Remission Induction | Methotrexate - adverse effects | Dexamethasone - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - therapeutic use | Vincristine - adverse effects | Hyperglycemia - etiology | Doxorubicin - adverse effects
Journal Article
Leukemia Research, ISSN 0145-2126, 2013, Volume 37, Issue 11, pp. 1592 - 1601
Journal Article
Journal Article
Cancer, ISSN 0008-543X, 10/2010, Volume 116, Issue 19, pp. 4580 - 4589
Journal Article
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 08/2017, Volume 23, Issue 8, pp. 1264 - 1268
Journal Article
Cancer, ISSN 0008-543X, 10/2017, Volume 123, Issue 19, pp. 3717 - 3724
BACKGROUND Tumor protein 53 (TP53) mutations are uncommon in adult patients with acute lymphoblastic leukemia (ALL) and predict a poor outcome. METHODS TP53... 
hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper‐CVAD) | tumor protein 53 (TP53) | acute lymphoblastic leukemia (ALL) | next‐generation sequencing | hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) | next-generation sequencing | SURVIVAL | vincristine | RELAPSE | and dexamethasone (hyper-CVAD) | IMPACT | THERAPY | GENE | ONCOLOGY | FREQUENCY | hyperfractionated cyclophosphamide | doxorubicin | MINIMAL RESIDUAL DISEASE | DELETIONS | CORRELATE | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Age Factors | Humans | Middle Aged | Male | Mutation, Missense | Tumor Suppressor Protein p53 - genetics | Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative - drug therapy | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Genes, p53 | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Aged, 80 and over | Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative - genetics | Vincristine - administration & dosage | Adult | Female | Doxorubicin - administration & dosage | Dexamethasone - administration & dosage | Treatment Outcome | Sequence Analysis, DNA | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - genetics | Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Alleles | Aged | Mutation | Dexamethasone | Cell survival | Acute lymphatic leukemia | Leukemia | p53 Protein | Blood cells | Lymphatic leukemia | Survival | Patients | Doxorubicin | Vincristine | Philadelphia chromosome | Cyclophosphamide | Lymphocytes B | Monoclonal antibodies | Remission | Deoxyribonucleic acid--DNA | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Cancer, ISSN 0008-543X, 03/2002, Volume 94, Issue 5, pp. 1492 - 1499
BACKGROUND Patients with acquired immunodeficiency syndrome (AIDS)‐associated lymphoma/leukemia have a poor prognosis and are frequently treated with... 
vincristine | highly active antiretroviral therapy | hyperfractionated cyclophosphamide | doxorubicin | Burkitt lymphoma/leukemia | and dexamethasone (hyper‐CVAD) | acquired immunodeficiency syndrome | Highly active antiretroviral therapy | Hyperfractionated cyclophosphamide | Acquired immunodeficiency syndrome | And dexamethasone (hyper-CVAD) | Doxorubicin | Vincristine | PROGNOSTIC FACTORS | DOSE METHOTREXATE | NONCLEAVED-CELL LYMPHOMA | AIDS | INFUSIONAL CYCLOPHOSPHAMIDE | and dexamethasone (hyper-CVAD) | HYPER-CVAD | NERVOUS-SYSTEM PROPHYLAXIS | ONCOLOGY | VIRUS-RELATED LYMPHOMA | ACUTE LYMPHOBLASTIC-LEUKEMIA | NON-HODGKINS-LYMPHOMA | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Dexamethasone - administration & dosage | Burkitt Lymphoma - virology | Drug Administration Schedule | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Treatment Outcome | Combined Modality Therapy | Thrombocytopenia - chemically induced | Antiretroviral Therapy, Highly Active | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Vincristine - administration & dosage | Adult | Female | Acquired Immunodeficiency Syndrome - complications | Neutropenia - chemically induced | Burkitt Lymphoma - drug therapy | Doxorubicin - administration & dosage
Journal Article
Journal Article
Cancer, ISSN 0008-543X, 12/2016, Volume 122, Issue 23, pp. 3650 - 3656
BACKGROUND The clinical efficacy of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (HCVAD) plus ponatinib has not been... 
dexamethasone (hyper‐CVAD [HCVAD]) | dasatinib | vincristine | acute lymphoblastic leukemia | hyperfractionated cyclophosphamide | ponatinib | doxorubicin | Philadelphia chromosome | dexamethasone (hyper-CVAD [HCVAD]) | ADULT PATIENTS | hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone (hyper-CVAD [HCVAD]) | ACUTE LYMPHOCYTIC-LEUKEMIA | REGIMEN | PHASE-2 | CHEMOTHERAPY | ONCOLOGY | TERM-FOLLOW-UP | IMATINIB MESYLATE | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Dexamethasone - administration & dosage | Prospective Studies | Humans | Middle Aged | Imidazoles - administration & dosage | Male | Survival Rate | Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics | Young Adult | Disease-Free Survival | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Propensity Score | Dasatinib - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyridazines - administration & dosage | Aged, 80 and over | Vincristine - administration & dosage | Adult | Female | Aged | Philadelphia Chromosome - drug effects | Doxorubicin - administration & dosage | Dasatinib | Care and treatment | Dosage and administration | Acute lymphocytic leukemia | Diagnosis | Research | Comparative analysis | Chromosomes
Journal Article
Hematology Journal, ISSN 1466-4860, 2004, Volume 5, Issue 2, pp. 112 - 117
Journal Article